Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 study of oral formulation of Foralumab to healthy volunteers for the treatment of Crohn's disease and NASH

Next Previous
Trial Profile

A Phase 1 study of oral formulation of Foralumab to healthy volunteers for the treatment of Crohn's disease and NASH

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 30 Dec 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Foralumab (Primary)
  • Indications Crohn's disease; Non-alcoholic steatohepatitis
  • Focus Adverse reactions

    • Most Recent Events

    • 29 Dec 2022 According to a Tiziana Life Sciences media release, this study was the first multiple-dose study with orally administered enteric-coated capsules of foralumab in patients with Crohns disease. Due to the refocus of the company subsequent to the first six months of 2022, this study has been placed on hold.
    • 29 Dec 2022 According to a Tiziana Life Sciences media release, the study completion is targeted for the fourth quarter of 2022.
    • 09 Jan 2020 Results presented in a Tiziana Life Sciences Media Release.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top